News
11-16-2011, 12:13 AM
Amgen announced today the publication of results from a Phase 3 trial (the '147 study) that evaluated XGEVA (denosumab) for use in preventing or delaying the onset of bone metastases in men with nonmetastatic castration-resistant prostate cancer.
More... (http://www.news-medical.net/news/20111116/Amgens-XGEVA-delays-onset-of-bone-metastases-in-men-with-prostate-cancer.aspx)
More... (http://www.news-medical.net/news/20111116/Amgens-XGEVA-delays-onset-of-bone-metastases-in-men-with-prostate-cancer.aspx)